ROS‐responsive drug delivery systems

Liang, Jing; Liu, Bin

doi:10.1002/btm2.10014

Cited by 191 publications

(76 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[10][11][12] Thes ide effects of chemotherapy are greatly suppressed by selective activation. [13][14][15][16][17][18] Many ROS-responsive prodrugs based on different ROS-sensitive linkers,s uch as aminoacrylate, [19][20][21][22] diselenide, [23] thioketal, [24] arylboronic ester, [25] and thioether [26] have been reported to show potential in clinical cancer treatment.Due to the disadvantages of each therapeutic practice,the co-delivery of two or more therapeutic agents has been developed to enable synergistic effects. [27,28] Theconstruction of co-delivery systems renders greater therapeutic effect compared to as ingle treatment modality.E ven though numerous studies have been reported in this field, [29][30][31] the lack of an effective method to fine-tune the ratio of co-loaded therapeutic agents has obstructed successful cancer treatment.…”

mentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

NIR‐Light‐Activated Combination Therapy with a Precise Ratio of Photosensitizer and Prodrug Using a Host–Guest Strategy

et al. 2019

View full text Add to dashboard Cite

The co‐delivery of photosensitizers with prodrugs sensitive to reactive oxygen species (ROS) for light‐triggered ROS generation and cascaded prodrug activation has drawn tremendous attention. However, the absence of a feasible method to deliver the two components at a precise ratio has impaired the application potential. Herein, we report an efficient method to produce a nanosized platform for the delivery of an optimized ratio of the two components by the means of host–guest strategy for maximizing the combination therapy efficacy of cancer treatment. The key features of this host–guest strategy for the combination therapy are that the ratio between photosensitizer and ROS‐sensitive prodrug can be easily tuned, near‐infrared (NIR) irradiation can sensitize the photosensitizer and activate the paclitaxel prodrug for its release, and the accumulation process can be tracked by NIR imaging to maximize the efficacy of photodynamic and chemotherapy.

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

NIR‐Light‐Activated Combination Therapy with a Precise Ratio of Photosensitizer and Prodrug Using a Host–Guest Strategy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Here, we showed that 16 μg RSV can be loaded into 1 mg of MSNPs after 3 days of physical adsorption, and the MSNPs rapidly release 90% of drug load after 5 days. Driven by the need for on-demand drug delivery, ROS-responsive materials have gained increasing interests [ 24 , 25 ]. To achieve the ROS responsive release of drug in a suitable concentration at the desired target area, various MSNPs-based stimuli-responsive drug release systems were developed using polyelectrolytes, lipid bilayer, or degradable polymers as gatekeepers [ 26 – 28 ].…”

Section: Discussionmentioning

confidence: 99%

ROS responsive resveratrol delivery from LDLR peptide conjugated PLA-coated mesoporous silica nanoparticles across the blood–brain barrier

et al. 2018

View full text Add to dashboard Cite

BackgroundOxidative stress acts as a trigger in the course of neurodegenerative diseases and neural injuries. An antioxidant-based therapy can be effective to ameliorate the deleterious effects of oxidative stress. Resveratrol (RSV) has been shown to be effective at removing excess reactive oxygen species (ROS) or reactive nitrogen species generation in the central nervous system (CNS), but the delivery of RSV into the brain through systemic administration is inefficient. Here, we have developed a RSV delivery vehicle based on polylactic acid (PLA)-coated mesoporous silica nanoparticles (MSNPs), conjugated with a ligand peptide of low-density lipoprotein receptor (LDLR) to enhance their transcytosis across the blood–brain barrier (BBB).ResultsResveratrol was loaded into MSNPs (average diameter 200 nm, pore size 4 nm) at 16 μg/mg (w/w). As a gatekeeper, the PLA coating prevented the RSV burst release, while ROS was shown to trigger the drug release by accelerating PLA degradation. An in vitro BBB model with a co-culture of rat brain microvascular endothelial cells (RBECs) and microglia cells using Transwell chambers was established to assess the RSV delivery across BBB. The conjugation of LDLR ligand peptides markedly enhanced the migration of MSNPs across the RBECs monolayer. RSV could be released and effectively reduce the activation of the microglia cells stimulated by phorbol-myristate-acetate or lipopolysaccharide.ConclusionsThese ROS responsive LDLR peptides conjugated PLA-coated MSNPs have great potential for oxidative stress therapy in CNS.Electronic supplementary materialThe online version of this article (10.1186/s12951-018-0340-7) contains supplementary material, which is available to authorized users.

show abstract

“…Thioether-containing polymers experience a phase transition from a hydrophobic (sulfide) state to a hydrophilic (sulfoxide-sulfone) state in the presence of an oxidative microenvironment. This phase transformation leads to the destabilization of the carrier, resulting in drug release [112]. Incorporation of a ketal into the poly-thioether prompts the development of dual stimuli-responsive polymers for protein delivery.…”

Section: Systems With Thioether Linkagementioning

confidence: 99%

Stimuli-Responsive Hydrogels for Local Post-Surgical Drug Delivery

Askari

Seyfoori

Amereh

et al. 2020

Gels

View full text Add to dashboard Cite

Currently, surgical operations, followed by systemic drug delivery, are the prevailing treatment modality for most diseases, including cancers and trauma-based injuries. Although effective to some extent, the side effects of surgery include inflammation, pain, a lower rate of tissue regeneration, disease recurrence, and the non-specific toxicity of chemotherapies, which remain significant clinical challenges. The localized delivery of therapeutics has recently emerged as an alternative to systemic therapy, which not only allows the delivery of higher doses of therapeutic agents to the surgical site, but also enables overcoming post-surgical complications, such as infections, inflammations, and pain. Due to the limitations of the current drug delivery systems, and an increasing clinical need for disease-specific drug release systems, hydrogels have attracted considerable interest, due to their unique properties, including a high capacity for drug loading, as well as a sustained release profile. Hydrogels can be used as local drug performance carriers as a means for diminishing the side effects of current systemic drug delivery methods and are suitable for the majority of surgery-based injuries. This work summarizes recent advances in hydrogel-based drug delivery systems (DDSs), including formulations such as implantable, injectable, and sprayable hydrogels, with a particular emphasis on stimuli-responsive materials. Moreover, clinical applications and future opportunities for this type of post-surgery treatment are also highlighted.

show abstract

ROS‐responsive drug delivery systems

Cited by 191 publications

References 72 publications

NIR‐Light‐Activated Combination Therapy with a Precise Ratio of Photosensitizer and Prodrug Using a Host–Guest Strategy

NIR‐Light‐Activated Combination Therapy with a Precise Ratio of Photosensitizer and Prodrug Using a Host–Guest Strategy

ROS responsive resveratrol delivery from LDLR peptide conjugated PLA-coated mesoporous silica nanoparticles across the blood–brain barrier

Stimuli-Responsive Hydrogels for Local Post-Surgical Drug Delivery

Contact Info

Product

Resources

About